Guidance, NICE advice and quality standards In development

Skip to filters Skip to results

Showing 51 to 75 of 384

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]	Technology appraisal guidance	13 November 2024
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]	Technology appraisal guidance	TBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]	Technology appraisal guidance	TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]	Technology appraisal guidance	13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]	Technology appraisal guidance	TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]	Technology appraisal guidance	5 March 2025
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]	Technology appraisal guidance	TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]	Technology appraisal guidance	23 October 2024
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure	NICE guideline	TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]	Technology appraisal guidance	TBC
Cladribine for treating relapsing multiple sclerosis ID6263	Technology appraisal guidance	5 February 2025
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]	Technology appraisal guidance	TBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment	Health technology evaluation	TBC
Colon cancer (adjuvant) - irinotecan [ID379]	Technology appraisal guidance	TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]	Technology appraisal guidance	TBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]	Technology appraisal guidance	16 October 2024
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]	Technology appraisal guidance	30 October 2024
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack	Diagnostics guidance	10 July 2024
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]	Technology appraisal guidance	11 September 2024
Dapagliflozin for treating chronic kidney disease [ID6411]	Technology appraisal guidance	12 February 2025

Results per page

10
25
50
All